☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Gene Therapy
Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis
July 9, 2021
Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease
June 9, 2021
Charles River to Acquire Vigene Biosciences for $292.5M
May 17, 2021
UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio
November 13, 2020
Kite's Tecartus (brexucabtagene autoleucel) Receives the US FDA's Approval as the First Cell-Based Gene Therapy for Relapsed or Re...
July 27, 2020
Castle Creek Collaborates with Fibrocell to Develop and Commercialize FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis...
April 16, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.